NCT00423124View on ClinicalTrials.gov

Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK in Patients With Haematological Malignancies

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

July 31, 2002

Primary Completion Date

December 31, 2011

Study Completion Date

November 30, 2013

Conditions
Hematological Malignancies
Interventions
GENETIC

HSV-TK

Infusion of genetically modified lymphocytes (1x10\^6-1x10\^7 c/kg): first at +21-+49 days after HSCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.

Trial Locations (8)

Unknown

Medizinische Hoschule Hannover, Hanover

G. Papanicolau, Thessaloniki

Hadassah University Hospital, Jerusalem

Fondazione San Raffaele, Milan

Istituto Clinico Humanitas, Milan

Policlinico Monteluce, Perugia

Ospedale Civile, Pescara

Hammersmith Hospital, London

Sponsors
All Listed Sponsors
lead

AGC Biologics S.p.A.

INDUSTRY